Characterizing the proteome of ES and better defining the molecular pathways specifically affected by the loss of SMARCB1 may help to define the molecular mechanisms of ES inception and progression and disclose novel therapeutic vulnerabilities. This evidence concerns the gene SMARCB1 and epithelioid sarcoma.